Skip to main content

Table 1 Baseline clinical characteristics of study population

From: Renal hemodynamic effects differ between antidiabetic combination strategies: randomized controlled clinical trial comparing empagliflozin/linagliptin with metformin/insulin glargine

Parameter

E+L group

M+I group

p-value

Age (years)

59.9 ± 9.8

60.7 ± 8.9

0.648

Diabetes duration (years)

7.2 ± 5.6

9.0 ± 5.3

0.092

RAS-blockade (−)

26 (51.0%)

27 (58.7%)

0.297

Weight (kg)

90.2 ± 14

93.1 ± 17

0.348

BMI (kg/m2)

30.4 ± 3.6

31.3 ± 3.9

0.222

Fasting plasma glucose (mg/dl)

156.2 ± 29

164.7 ± 34

0.240

HbA1c (%/mmol/mol)

7.69 ± 0.7/61 ± 7.7

7.73 ± 0.8/61 ± 8.7

0.780

Office systolic BP (mmHg)

132 ± 13

131 ± 13

0.774

Office diastolic BP (mmHg)

80 ± 8

78 ± 9

0.489

Office heart rate (beats/min)

71.3 ± 10

72.2 ± 10

0.671

  1. Data are means ± SD or n (%)
  2. RAS: renin-angiotensin system; BP: blood pressure